Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec Ltd
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
The primary objective of this study is to determine whether BG00012 is effective in reducing the rate of clinical relapses at 2 years.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination with Rituximab for Subjects with Relapsed, Follicular Non-Hodgkin’s Lymphoma who Previously Responded on Study 114-NH-301
To assess the safety of repeat or initial treatment with galiximab in combination with rituximab after relapse in the pivotal Phase III study (114-NH-301)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a nonsteroidal aromatase inhibitor
The primary objective of this study is to assess the efficacy of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had progressed following treatment with a ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis
The primary objective of this study is to determine whether BG00012, when compared with placebo, is effective in reducing the proportion of relapsing subjects at 2 years.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis
The primary objective of this study is to assess the potential of baminercept as an agent for inducing clinical response at Week 12 in subjects with moderate to severe UC.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis
To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing MS. The number and percentage of subjects who develop neutralizing antibodies (NAbs) ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Randomized, Open-Label, Multicenter, Phase 2/3 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia
To determine the effectiveness of lumiliximab when used in combination with Fludarabine, Cyclophosfamide and Rituximab (FCR) compared with Fludarabine, Cyclophosphamide and Rituximab (FCR) alone for t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
TYSABRI Long Term Re-Dosing Study
Initial Treatment Period: To further evaluate the safety of natalizumab monotherapy by: 1) evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab and 2) co...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
Estudio aleatorizado de interrrupción de tratamiento con Natalizumab" "Randomized Treatment Interruption of Natalizumab
1.Cómo evoluciona la recuperación de la función inmunitaria, utilizando los marcadores indirectos 2. Cómo evoluciona la reaparición de pruebas radiológicas y/o clínicas de actividad de la EM 3. El ef...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
Multicentre, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis
Primary objective: To determine whether DAC HYP, when compared to placebo, is effective in reducing the rate of relapse between baseline and week 52
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
Next